Polycystic Ovary Syndrome Market By Treatment Type (Medication [Oral Contraceptives, Anti-Androgens, Insulin-Sensitizing Agents, Gonadotropins, and Fertility Drugs], Surgery [Ovarian wedge resection, Laparoscopic ovarian drilling, and Other surgeries], and Others), By Drug Class (Hormonal Drugs, Anti-diabetics, Anti-obesity Drugs, and Anti-depressants), By Diagnosis (Ultrasound, Blood Tests, Physical Examination, and Pelvic Exam), and By End-User (Hospitals, Fertility Clinics, Ambulatory Surgical Centers, and Diagnostic Centers) Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

Polycystic Ovary Syndrome market accounted for USD 5.82 Billion in 2024 and is expected to reach USD 12.6 Billion by 2035, growing at a CAGR of around 7.3% between 2025 and 2035. Polycystic Ovary Syndrome (PCOS) Market is focused on disease diagnosis, treatment, and management of PCOS. It is a common hormonal disorder in women. Irregular menstrual cycles, infertility, and acne are some of the symptoms addressed by using pharmaceutical drugs, medical devices, and diagnostic tools. In this market, firms produce hormonal contraceptives and insulin sensitizers, along with diagnostic kits and lifestyle management products. The market growth is driven by increasing awareness about PCOS and a growing patient population.

Report Scope:

Market Dynamics

Advancements in diagnostic technologies improving early and accurate detection

Polycystic Ovary Syndrome (PCOS) Market is growing due to advanced diagnostic technology, which has improved early and accurate disorder diagnosis. Health practitioners diagnose PCOS better with advanced diagnostic techniques and equipment such as ultrasound imaging, hormonal profiling, and modern genetic and genomics technologies. Having a proper diagnosis timely allows the use of hormonal therapy and better diagnostics, assisting in minimizing long-term risks such as infertility, cardiovascular problems, and type 2 diabetes. Besides, the developments in early diagnosis can be attributed to increased healthcare needs, enhanced awareness among women, and a rise in healthcare infrastructure.

Limited awareness and diagnosis in developing and rural regions

Lack of awareness and diagnosis regarding polycystic ovarian syndrome (PCOS) in developing or rural areas is a major barrier to the market. Many ladies are left undiagnosed due to healthcare infrastructure, specialized medical practitioners, and a lack of information on PCOS symptoms. In rural areas where healthcare facilities are limited, this problem becomes worse. There are educational programs related to women’s health that promote prevention measures against such disorders. Therefore, the need for diagnostics or management is higher in these locations, which curtails growth potential for the PCOS treatment industry. Awareness campaigns are expanded, and improved healthcare is considered to address such barriers.

Development of non-invasive diagnostic tools for early Polycystic Ovary Syndrome detection

The advancement of non-invasive diagnosis tools for the early detection of polycystic ovary syndrome (PCOS) is transforming potential in the PCOS market. Hormone-level testing, ultrasound scans, and symptom assessment are used for diagnosis, but they fail to detect PCOS in an early stage. Innovative non-invasive solutions like advanced blood biomarkers, saliva-based tests, or metabolic and hormonal fluctuations tracking wearable devices improve the accuracy of diagnosis. This facilitates customized treatment that helps to prevent long-term complications like cardiovascular diseases and infertility. It increases the need for patient-friendly diagnosis options that minimize invasive procedures, making patients cooperative and comfortable.

Industry Experts Opinion

“PCOS is not well understood. It’s really hard to diagnose when people are on contraception.”

• Professor Helena Teede, Director of Monash Centre for Health Research Implementation, Monash University.

"A diagnosis of PCOS is almost always associated with an assumption that getting pregnant will be a challenge. PCOS is one of the main causes of infertility."

• Dr Vandana Hegde, Clinical Director - Hegde Fertility, Hyderabad.

Segment Analysis

Based on the treatment type, the Polycystic Ovary Syndrome Market is classified into Medication such as Oral Contraceptives, Anti-Androgens, Insulin-Sensitizing Agents, Gonadotropins, and Fertility Drugs, Surgery options such as Ovarian wedge resection, Laparoscopic ovarian drilling, and Others. The medication is dominant because it involves symptom management. In this, oral contraceptives and insulin-sensitizing agents stand out as they provide efficient, non-invasive solutions for hormonal imbalance management. This segment gains importance from various factors, including availability, widespread applicability, and the continuous emergence of better medications that dominate the PCOS treatment area.

Based on the diagnosis, the Polycystic Ovary Syndrome Market is classified into Ultrasound, Blood Tests, Physical Examination, and Pelvic Exam. Ultrasound is a significant diagnostic tool for this segment. Due to its non-invasive capability of providing detailed pictures of the ovaries, it is a popular tool in identifying cysts and other irregularities related to PCOS. It is essential in illness diagnosis and disease monitoring because it makes the arrangement of the ovaries visible. Furthermore, physical examinations, blood tests, and pelvic exams are important, but ultrasound is the preferred method for diagnosing PCOS due to its accuracy.

Regional Analysis

Polycystic Ovary Syndrome (PCOS) Market is leading in North America due to advances in diagnostic and therapeutic approaches, increased awareness of women's health, and the rise in hormonal disorders. The United States leads because of its strong healthcare system, patient knowledge, and major research funding in reproductive health. Furthermore, Canada plays a significant role in increasing interest in early diagnosis and management to improve reproductive health. Key players in this market introduce new drugs and fertility treatments while there are increasing lifestyle diseases such as obesity or diabetes that contribute towards promoting PCOS management across North America.

Polycystic Ovary Syndrome (PCOS) Market is expanding in Europe due to growing evidence of other metabolic disorders like diabetes and obesity. Major countries like Germany, France, and the United Kingdom are advancing healthcare systems, rising diagnoses, and government policies that promote women’s health. Consequently, hormone therapy and fertility solutions are innovative therapies that are needed. Furthermore, several recent projects focusing on the genetic and environmental factors that contribute to PCOS are developing innovative treatment strategies.

Competitive Landscape

The Polycystic Ovary Syndrome (PCOS) market is highly competitive, with top pharmaceutical companies in the development of hormonal therapies, fertility treatments, and metabolic disorders management. Important distributors in this market include Teva Pharmaceutical Industries Ltd., Bayer AG, Abbott Laboratories, Merck & Co., Bristol-Myers Squibb, Sanofi S.A., and Pfizer Inc. Abbott Laboratories is enhancing its diagnostic equipment for early detection, including differential diagnosis. Furthermore, Merck & Co. is focused on infertility treatments, a vital issue for women with PCOS who are trying to have children. The increased focus on new product development and drug therapy has resulted in increased competition in this market.

Polycystic Ovary Syndrome Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In July 2024, the research published in Science "showed that artemisinins were effective in reducing symptoms associated with PCOS in both rodent models and human patients." Put simply, it has been reported that an anti-malaria medication can treat this thyroid imbalance-related condition.
• In December 2023, The US-based Metabolon was granted by the National Institute of Health (NIH) to develop more precise diagnostics for PCOS, or polycystic ovarian syndrome.

Report Coverage:

By Treatment Type

• Medication
  • Oral Contraceptives
  • Anti-Androgens
  • Insulin-Sensitizing Agents
  • Gonadotropins
  • Fertility Drugs
• Surgery
  • Ovarian wedge resection
  • Laparoscopic ovarian drilling
  • Other surgeries
• Others

By Drug Class

• Hormonal Drugs
• Anti-diabetics
• Anti-obesity Drugs
• Anti-depressants

By Diagnosis

• Ultrasound
• Blood Tests
• Physical Examination
• Pelvic Exam

By End-User

• Hospitals
• Fertility Clinics
• Ambulatory Surgical Centers
• Diagnostic Centers

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Teva Pharmaceutical Industries Ltd.
• Bayer AG
• Abbott Laboratories
• Merck & Co., Inc.
• Bristol-Myers Squibb
• Ferring Pharmaceuticals
• Sanofi S.A.
• AstraZeneca
• Novartis AG
• GlaxoSmithKline plc (GSK)
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Johnson & Johnson
• Sun Pharmaceutical Industries Ltd.
• Ipsen Pharma

Frequently Asked Questions (FAQs)